246 related articles for article (PubMed ID: 12385678)
21. Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000/125 milligrams) versus those of amoxicillin-clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults.
File TM; Lode H; Kurz H; Kozak R; Xie H; Berkowitz E;
Antimicrob Agents Chemother; 2004 Sep; 48(9):3323-31. PubMed ID: 15328092
[TBL] [Abstract][Full Text] [Related]
22. [Pharmacodynamic basis for the use of amoxicillin-clavulanic acid in respiratory infections due to Streptococcus pneumoniae: In vitro studies in an experimental model].
Gómez-Lus ML; García Y; Valero E; Amores R; Fuentes F
Rev Esp Quimioter; 2000 Sep; 13(3):306-13. PubMed ID: 11086282
[TBL] [Abstract][Full Text] [Related]
23. [Sinusal penetration of amoxicillin-clavulanic acid. Formulation 1 g./125 mg., twice daily versus formulation 500 mg./125 mg., three times daily].
Jehl F; Klossek JM; Peynegre R; Serrano E; Castillo L; Bobin S; Desprez D; Renault C; Neel V; Rouffiac E; Borie C
Presse Med; 2002 Oct; 31(34):1596-603. PubMed ID: 12426976
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the efficacy and safety of a short course of ceftibuten with that of amoxycillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis.
Guest N; Langan CE
Int J Antimicrob Agents; 1998 Apr; 10(1):49-54. PubMed ID: 9624543
[TBL] [Abstract][Full Text] [Related]
25. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from adults in China during 2009 and 2010].
Wang H; Liu YL; Chen MJ; Xu YC; Sun HL; Yang QW; Hu YJ; Cao B; Chu YZ; Liu Y; Zhang R; Yu YS; Sun ZY; Zhuo C; Ni YX; Hu BJ
Zhonghua Jie He He Hu Xi Za Zhi; 2012 Feb; 35(2):113-9. PubMed ID: 22455967
[TBL] [Abstract][Full Text] [Related]
26. Comparative in-vitro activity of levofloxacin against isolates of bacteria from adult patients with community-acquired lower respiratory tract infections.
Casellas JM; Gilardoni M; Tome G; Goldberg M; Ivanovic S; Orduna M; Dolmann A; Ascoli M; Ariza H; Montero JM
J Antimicrob Chemother; 1999 Jun; 43 Suppl C():37-42. PubMed ID: 10404336
[TBL] [Abstract][Full Text] [Related]
27. Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone.
Rosón B; Carratalà J; Tubau F; Dorca J; Liñares J; Pallares R; Manresa F; Gudiol F
Microb Drug Resist; 2001; 7(1):85-96. PubMed ID: 11310807
[TBL] [Abstract][Full Text] [Related]
28. Two pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae.
Woodnutt G; Berry V
Antimicrob Agents Chemother; 1999 Jan; 43(1):29-34. PubMed ID: 9869561
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of high-dose amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae.
Woodnutt G; Berry V
Antimicrob Agents Chemother; 1999 Jan; 43(1):35-40. PubMed ID: 9869562
[TBL] [Abstract][Full Text] [Related]
30. Extended release amoxicillin/clavulanate: optimizing a product for respiratory infections based on pharmacodynamic principles.
Jacobs MR
Expert Rev Anti Infect Ther; 2005 Jun; 3(3):353-60. PubMed ID: 15954852
[TBL] [Abstract][Full Text] [Related]
31. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group.
Thornsberry C; Ogilvie P; Kahn J; Mauriz Y
Diagn Microbiol Infect Dis; 1997 Dec; 29(4):249-57. PubMed ID: 9458982
[TBL] [Abstract][Full Text] [Related]
32. Amoxycillin/clavulanate in acute purulent exacerbations of chronic bronchitis.
Maesen FP; Davies BI; Baur C
J Antimicrob Chemother; 1987 Mar; 19(3):373-83. PubMed ID: 3494724
[TBL] [Abstract][Full Text] [Related]
33. [Resistance study of community respiratory pathogens isolated in China from 2005 to 2007].
Sun HL; Yang QW; Xu YC; Wang H; Xie XL; Chen MJ; Zhang XZ; Liu Y; Ye HF; Sun ZY; Duan Q; Ni YX; Yu YS; Zhao WS; He L; Wang J; Ji P; Liu PP; Zhang LX
Zhonghua Yi Xue Za Zhi; 2009 Nov; 89(42):2983-7. PubMed ID: 20137709
[TBL] [Abstract][Full Text] [Related]
34. Large dosage amoxicillin/clavulanate, compared with azithromycin, for the treatment of bacterial acute otitis media in children.
Hoberman A; Dagan R; Leibovitz E; Rosenblut A; Johnson CE; Huff A; Bandekar R; Wynne B
Pediatr Infect Dis J; 2005 Jun; 24(6):525-32. PubMed ID: 15933563
[TBL] [Abstract][Full Text] [Related]
35. Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia.
O'Doherty B; Dutchman DA; Pettit R; Maroli A
J Antimicrob Chemother; 1997 Dec; 40 Suppl A():73-81. PubMed ID: 9484876
[TBL] [Abstract][Full Text] [Related]
36. Susceptibility patterns of Streptococcus pneumoniae isolates in North America (2002-2003): contemporary in vitro activities of amoxicillin/clavulanate and 15 other antimicrobial agents.
Pottumarthy S; Fritsche TR; Sader HS; Stilwell MG; Jones RN
Int J Antimicrob Agents; 2005 Apr; 25(4):282-9. PubMed ID: 15784306
[TBL] [Abstract][Full Text] [Related]
37. Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae.
Berry V; Thorburn CE; Knott SJ; Woodnutt G
Antimicrob Agents Chemother; 1998 Dec; 42(12):3193-9. PubMed ID: 9835514
[TBL] [Abstract][Full Text] [Related]
38. Multicenter trial of cefpodoxime proxetil vs. amoxicillin-clavulanate in acute lower respiratory tract infections in childhood. International Study Group.
Klein M
Pediatr Infect Dis J; 1995 Apr; 14(4 Suppl):S19-22. PubMed ID: 7792126
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of twice-daily amoxycillin/clavulanate in lower respiratory tract infections.
Balgos AA; Rodriguez-Gomez G; Nasnas R; Mahasur AA; Margono BP; Tinoco-Favila JC; Sansores-Martinez RH; Hassan M; Beppo O; Wongsa A; Cukier A; Vargas F
Int J Clin Pract; 1999; 53(5):325-30. PubMed ID: 10695094
[TBL] [Abstract][Full Text] [Related]
40. [Antimicrobial susceptibility of Streptococcus pyogenes, Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis from community acquired respiratory infections in 2000].
Melo-Cristino J; Fernandes ML; Serrano N;
Acta Med Port; 2001; 14(5-6):459-68. PubMed ID: 11878155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
